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Background: Vaccine treatment using multiple peptides derived from multiple proteins is considered to be a
promising option for cancer immune therapy, but scientific evidence supporting the therapeutic efficacy of multiple
peptides is limited.
Methods: We conducted phase I trials using a mixture of multiple therapeutic peptide vaccines to evaluate their
safety, immunogenicity and clinical response in patients with advanced/recurrent NSCLC. We administered two
different combinations of four HLA-A24-restricted peptides. Two were peptides derived from vascular endothelial
growth factor receptor 1 (VEGFR1) and 2 (VEGFR2), and the third was a peptide derived from up-regulated lung
cancer 10 (URLC10, which is also called lymphocyte antigen 6 complex locus K [LY6K]). The fourth peptide used
was derived from TTK protein kinase (TTK) or cell division associated 1 (CDCA1). Vaccines were administered weekly
by subcutaneous injection into the axillary region of patients with montanide ISA-51 incomplete Freund’s adjuvant,
until the disease was judged to have progressed or patients requested to be withdrawn from the trial.
Immunological responses were primarily evaluated using an IFN-gamma ELiSPOT assay.
Results: Vaccinations were well tolerated with no severe treatment-associated adverse events except for the
reactions that occurred at the injection sites. Peptide-specific T cell responses against at least one peptide were
observed in 13 of the 15 patients enrolled. Although no patient exhibited complete or partial responses, seven
patients (47%) had stable disease for at least 2 months. The median overall survival time was 398 days, and the 1-
and 2-year survival rates were 58.3% and 32.8%, respectively.
Conclusion: Peptide vaccine therapy using a mixture of four novel peptides was found to be safe, and is expected
to induce strong specific T cell responses.
Trial registration: These studies were registered with ClinicalTrials.gov NCT00633724 and NCT00874588.
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Lung cancer is the leading cause of cancer death in the
world [1]. Despite the recent development of novel treat-
ment modalities for patients with non-small cell lung
cancer (NSCLC), survival rates are still unsatisfactory
[2]. Furthermore, although molecular-targeted drugs are
expected to cause fewer serious adverse events associ-
ated with the use of cytotoxic chemotherapeutic agents,
but still cause some [3,4]. Therefore, the development of
more effective and less toxic therapeutic modalities is
eagerly awaited. In this regard, cancer immunotherapy is
considered to be a promising option with minimum tox-
icity, but its effectiveness has not yet been proven to be
superior to the presently available treatments. However,
several ongoing clinical trials that are administering vac-
cines, such as MAGE-A3 or BLP25 for lung cancer as an
adjuvant treatment or in a maintenance setting after
standard chemotherapy, seem to be very promising [5,6].
Although these lung cancer trials have involved the ad-
ministration of a single vaccine, a combination of mul-
tiple peptide vaccines has also been used in several types
of solid cancer [7,8].
We have previously identified novel cancer-testis anti-
gens, including up-regulated lung cancer 10 (URLC10;
also called lymphocyte antigen 6 complex locus K [LY6K])
[9], TTK protein kinase (TTK) [10] and the cell division
cycle associated gene 1 (CDCA1) [11], that were found to




1 54/M Recurrence AD LN, bone
2 48/M IIIB AD PM, effusion
3 65/M Recurrence AD PM
4 58/M IV AD Primary, bone
5 60/M IV AD Primary, LN
6 47/M IV AD Primary, LN, ADR
7 40/M IIIA AD Primary, LN
8 69/M Recurrence SQ PM
9 65/M Recurrence AD Dissemination
10 57/M Recurrence PLEO LN
11 55/F IIIB AD Primary, LN, effusion
12 62/M Recurrence AD PM
13 68/F IV AD Primary, bone, effusion
14 39/F IV NSCLC Primary, liver, bone
15 61/M Recurrence AD PM, LN
*AD: adenocarcinoma; SQ: squamous cell carcinoma; PLEO: pleomorphic carcinoma
was not possible.
§LN: lymph nodes metastasis; bone: bone metastasis; PM: pulmonary metastasis; ef
metastasis; Dissemination: pleural dissemination; liver: liver metastasis.
† L: LY6K; T: TTK; R1: VEGFR1; R2: VEGFR2; C: CDCA1.
**PLT: platinum containing chemotherapy; RT: radiotherapy; EGFR-TKI: epidermal grgenome-wide cDNA microarray method. We have also
previously reported peptide vaccines that target VEGFR1
[12] and VEGFR2 [13]. To induce a higher level of cyto-
toxic T lymphocytes (CTLs), also known as cytotoxic T
cells, that have direct cancer cell killing activity or block
the blood supply to cancer cells, we attempted to combine
the peptides derived from cancer-testis antigens, as well as
those designed to induce an anti-angiogenic effect to
achieve an effective response in patients with advanced
NSCLC. In the current study we report on the safety of
combination therapy involving multiple peptides and a
possible improvement in patient prognosis.
Methods
Study design
We performed two phase I clinical trials using two diffe-
rent combinations of peptide vaccines. In the first trial,
we administered peptides derived from URLC10, TTK,
VEGFR1 and VEGFR2, and in the second trial we admin-
istered peptides derived from URLC10, CDCA1, VEGFR1
and VEGFR2. All peptides were restricted to HLA-A*2402.
Fifteen HLA-24-positive patients with NSCLC who failed
to respond to the standard therapy were enrolled in the
three patient/dose/cohort phase I trial involving 0.5, 1 or
3 mg/body for each peptide (for trial 1), or 1 or 3 mg/body
for each peptide (for trial 2). The clinical characteristics
and treatment information for all patients enrolled in
the study are summarized in Table 1. Vaccines werePerformance status
(ECOG)
Peptides† Dose (mg) Phase of treatment
(Prior therapy**)
2 L, T, R1, R2 0.5 5th (PLT, RT)
2 L, T, R1, R2 0.5 5th (PLT)
2 L, T, R1, R2 0.5 6th (PLT, EGFR-TKI)
2 L, T, R1, R2 1 4th (PLT)
1 L, T, R1, R2 1 3rd (PLT)
0 L, T, R1, R2 1 3rd(PLT, RT)
1 L, T, R1, R2 3 3rd(PLT)
1 L, T, R1, R2 3 3rd(PLT, RT)
0 L, T, R1, R2 3 2nd(PLT, RT)
1 L, C, R1, R2 1 3rd(PLT, RT)
2 L, C, R1, R2 1 5th(PLT, EGFR-TKI)
1 L, C, R1, R2 1 2nd(PLT)
2 L, C, R1, R2 3 2nd(PLT)
2 L, C, R1, R2 3 2nd(PLT, RT)
1 L, C, R1, R2 3 5th(PLT, RT, EGFR-TKI)
; NSCLC: non-small cell lung cancer in which further histological determination
fusion: malignant pleural effusion; Primary: primary tumor; ADR: adrenal gland
owth factor receptor tyrosine kinase inhibitor.
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tated weekly. Administration was by subcutaneous injec-
tion into the patient’s axillary region after mixing with
incomplete Freund’s adjuvant (IFA) Montanide ISA 51,
SEPPIC until progression of the disease was observed, or
until the patient declined the continuation of the vaccine
treatment. Immunological responses were evaluated by
means of INF-gamma ELISPOT assays. Every measurable
lesion was evaluated using response evaluation criteria in
solid tumors (RECIST) 1.0, and the toxicities caused by the
vaccination therapy were assessed using Common Termin-
ology Criteria for Adverse Events (CTCAE) version 3.
These studies were approved by the ethical committee of
Fukushima Medical University (trial 1 approval number:
554; trial 2 approval number: 810) and were registered
with ClinicalTrials.gov (trial 1: NCT00633724; trial 2:
NCT00874588). Written informed consent was obtained
from all individuals. The trials were carried out in accord-
ance with the Helsinki declaration on experimentation on
human subjects.
Patient eligibility
Patients with an advanced or a recurrent non-small cell
lung cancer who failed to respond to the standard therapy
were enrolled in these two trials. Eligibility criteria were as
follows: (1) patients who had an HLA-A*2402 allele evalu-
ated using DNA genotyping; (2) adequate bone-marrow,
cardiac, pulmonary, hepatic and renal functions including
a white blood cell count of 1500-15000/mm3, a platelet
count of >75 000/mm3, total bilirubin of < three times that
of the institutional normal upper limit, levels of aspartate
aminotransferase, alanine aminotransferase, and alkaline
phosphatase of < three times that of the institutional nor-
mal upper limits, and levels of creatinine of < two times
the institutional normal upper limit; (3) no other therapy
for lung cancer within 4 weeks prior to the initiation of
the trial; (4) an ECOG performance status of 0–2; and
(f) an age of ≥20 years. The exclusion criteria for patients
participating in the two clinical trials were as follows:
(1) pregnancy (including women of childbearing poten-
tial); (2) breast feeding; (3) bleeding disorder; (4) infections
requiring antibiotics treatment; (5) concomitant treatment
with steroid or immunosuppressant; and (6) decision of un-
suitableness by principal investigator or physician-in-charge.
Peptides
The amino acid sequences of the peptides used were
RYCNLEGPPI (URLC19-177), VYGIRLEHF (CDCA1-56),
SYRNEIAYL (TTK-567), TLFWLLLTL (VEGFR1-770) and
RFVPDGNRI (VEGFR2-169); these were expected to bind
to an HLA-A24 molecule. These peptides were synthesized
as GMP grade as described elsewhere [10-13]. The purity
(>97%) and identity of the peptides were determined using
analytical high-performance liquid chromatography andmass spectrometry analysis, respectively. Peptides were
dissolved in dimethyl-sulfoxide at the concentration of
20 mg/ml and stored at −80°C.
Enzyme-linked immunospot (ELISPOT) assay
Specific CTL response was measured using an ELISPOT
assay following in vitro sensitization. Frozen peripheral
blood mononuclear cells (PBMCs) isolated from each
patient were thawed, and the viability was confirmed to
be more than 90%. 500,000 PBMC cells from each pa-
tient were cultured with 10 mg/ml of respective peptide
and 100 IU/ml of IL-2 (Novartis, Emeryville, CA, USA)
at 37°C for two weeks (each peptide was added to the
culture medium on days 0 and 7). After CD4+ cell deple-
tion using a Dynal CD4-positive isolation kit (Invitrogen,
Carlsbad, CA, USA), the IFN-γ ELISPOT assay was
performed using a Human IFN-γ ELISpot PLUS kit
(MabTech, Nacka Strand, Sweden) according to the
manufacturers’ instructions. Briefly, HLA-A*2402-posi-
tive B-lymphoblast TISI cells (IHWG Cell and Gene
Bank, Seattle, WA, USA) were incubated with 20 mg/ml
of each peptide overnight, then the peptide in the media
was washed out to prepare the peptide-pulsed TISI cells
as stimulator cells. Prepared CD4-negative cells were
cultured with the peptide-pulsed TISI cells (2 × 104
cells/well) at the ratio of responder cells and stimulator
cells (R/S ratio) of 1:1, 1:2, 1:4 and 1:8 on 96-well plates
at 37°C overnight. Non-peptide-pulsed TISI cells were
used as negative controls. To confirm the IFN-γ prod-
uctivity, responder cells (2.5 × 103 cells/well) were stim-
ulated with PMA (66 ng/ml) and ionomycin (3 mg/ml)
without stimulator cells overnight, and then applied to
the IFN-γ ELISPOT assay. All ELISPOT assays were
performed in triplicate wells. The plates were analyzed
using the automated ELISPOT reader, ImmunoSPOT S4
(Cellular Technology Ltd, Shaker Heights, OH, USA)
and ImmunoSpot Professional Software Version 5.0
(Cellular Technology Ltd). The number of peptide spe-
cific spots was calculated by subtracting the spot num-
ber in the control well from the spot number in well
with peptide-pulsed TISI cells. Antigen specific CTL re-
sponses were classified into 4 groups (−, +, ++ or +++)
according to a previously reported protocol [14]. If the
CTLs were indicated as +, we judged them as being
positive in this study. The quality of our ELISPOT assay
was ranked at the average level by the ELISPOT panel of
Cancer Immunotherapy Consortium (CIC; http://cvc.
assaymgmt.webbasix.com).
Flow cytometrical analysis
The presence of CTLs with peptide-specific T cell re-
ceptor was analyzed using a FACS-CantoII (Becton
Dickinson, San Jose, CA, USA), using VEGFR1 or
VEGFR2-derived epitope peptide-MHC dextramer-PE
Table 2 Summary of toxicity in Trial 1 using the TTK containing vaccine
Vaccine doses 0.5 mg (n=3) 1.0 mg (n=3) 3.0 mg (n=3) Total patients (n=9)
Grade Grade Grade (%)
1-2 3(4) 1-2 3(4) 1-2 3(4)
Blood/bone marrow
Anemia 1 0 1 0 2 0 3 (33%)
Leukopenia 0 0 1 0 0 0 1 (11%)
Constitutional symptoms
Fatigue 1 0 2 0 1 0 4 (44%)
Gastrointestinal
Nausea/vomiting 0 0 2 0 1 0 3 (33%)
Anorexia 0 1 2 0 0 0 3 (33%)
Constipation 0 0 1 0 0 0 1 (11%)
Dermatology/skin
Rash 2 0 2 0 3 0 7 (77%)
Pruritus 0 0 1 0 2 0 3 (33%)
Reaction at the injection site 2 0 2 0 3 0 7 (77%)
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epitope peptide-MHC pentamer-PE (ProImmune Ltd.,
Oxford, UK), or URLC10-derived epitope peptide-MHC
tetramer-PE (Medical & Biological Laboratories Co., Ltd.,
Nagoya, Japan) according to the manufacturers’ in-
structions. HIV-derived epitope peptide (RYLRDQQLL)-
MHC dextramer, pentamer or tetramer-PE was used as aTable 3 Summary of toxicity in Trial 2 using the CDCA1 conta







Elevated AST 0 0











Reaction at the injection site 3 0negative control. Briefly, cells were incubated with the
peptide-MHC dextramer, pentamer or tetramer-PE for
10 min at room temperature, and then treated with FITC-
conjugated anti-human CD8 mAb, APC-conjugated anti-
human CD3 mAb, PE-Cy7-conjugated anti-human CD4
mAb, and 7-AAD (BD Pharmingen, San Diego, CA, USA)
at 4°C for 20 min.ining vaccine
3.0 mg (n=3) Total patients (n=6)
Grade (%)
1-2 3(4)
2 0 4 (67)
1 0 1 (17)
0 (1) 1 (17)
0 (1) 1 (17)
3 0 3 (50)
1 0 2 (33)
2 0 2 (33)
2 0 2 (33)
0 0 1 (17)
3 0 6 (100)
2 0 5 (83)
3 0 6 (100)







T cell response After
treatmentLY6K TTK CDCA1 R1 R2
1 1 PD 15 112 - ++ - ++ None
2 1 PD 29 36 - + - ++ None
3 1 PD 43 53 - + ++ + None
4 1 PD 33 33 - - - - None
5 2 PD 53 398 - - - - EGFR-TKI
6 5 SD 86 834 + - - - RT
7 1 PD 28 276 - + - ++ None
8 4 SD 476 476 +++ +++ +++ +++ None
9 25 SD 400 858 +++ +++ +++ ++ None
10 9 SD 200 756 +++ +++ + +++ EGFR-TKI
11 3 PD 60 265 +++ +++ - + None
12 19 SD 490 705* +++ +++ +++ ++ Cx
13 4 PD 53 282 ++ ++ + - None
14 6 SD 83 213 +++ +++ +++ +++ None
15 13 SD 316 571* +++ +++ + ++ Immune**
*: patients still alive; **: another immunotherapy; †PFS: progression free survival; §OS: overall survival.
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Statistical analysis for correlation between clinical re-
sponse and reaction at the injection site (RAI) was
performed Fisher’s exact test. Overall survival rates were
analyzed using the Kaplan-Meier method, and survival
was measured in days from the first vaccination to
death. Statistical significance of the survival period was
analyzed using the log-rank test.
Results
Clinical characteristics of the enrolled patients
The clinical characteristics of the enrolled patients are
summarized in Table 1. Eight advanced-stage patients
and seven patients with recurrence after surgery were
enrolled in the trials. The mean age of these patients
was 56.5 years (±7.5 years). Twelve patients were diag-
nosed as having adenocarcinoma including two cases with
sensitive EGFR mutations (Patients 5 and 12), and there
was one patient with squamous cell carcinoma, one pa-
tient with pleomorphic carcinoma; the remaining patient
was diagnosed as having non-histologically-specified non-
small cell lung cancer. The patients had received at least
one type of chemotherapy regime prior to enrollment as
shown in Table 1.
Feasibility and adverse reactions
The toxicities observed in the 15 patients are summa-
rized in Tables 2 and 3. There was no severe adverse
event considered to be related to the vaccination except
for local reactions at the injection sites. Although one
patient revealed the elevation of hepatic transaminasesequivalent to grade 4 toxicity, we judged that this was
not due to the vaccine-related toxicity, but was caused
by massive liver metastasis.
Monitoring of immunological responses and clinical
response
PBMCs were obtained from all patients before the vaccine
treatment and after every course (one course consists of
four vaccinations), and in some patients every month after
the vaccine treatment had been completed. Using these
PBMCs, we analyzed the levels of peptide-specific CTL re-
sponses as shown in Table 4 and Additional file 1: Table
S2. Immunological responses were found to be relatively
weak in the 0.5 mg/body and 1 mg/body groups relative
to the 3 mg/body group in Trial 1. Hence, in Trial 2 we
deleted the 0.5 mg/body group and administered 1.0 and
3.0 mg/body. In the 3.0 mg/body group, four of a total of
six patients in both of the trials revealed strong CTL re-
sponses for at least two kinds of peptides.
When we analyzed CTL induction according to perfor-
mance status (PS), we only detected a strong CTL response
in two out of the seven patients with PS 2, while we ob-
served strong CTL responses in five out of the eight
patients with PS 0 or 1. In addition, among the seven pa-
tients that showed strong CTL responses, six patients were
judged as being in a stable condition using RECIST criteria
for at least 2 months. On the other hand, among the eight
patients who did not reveal a strong CTL response, seven
patients showed rapid progression.
A representative case of stable disease is shown in




















Figure 1 Strong injection site reaction in patient 8 with positive immune response. (a) Representative picture showing a positive immune
reaction at the local injection site (axillary region in patient 8; Grade 2 reaction categorized using CTCAE). (b) HLA-tetramer assay showing a very
high level of URLC10-specific CD8-positive cells (44.6% of CD8-positive cells) observed after the 4-month vaccine treatment in patient 8.
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strong local reaction at the injection sites and tumors were
maintained in a stable condition for 4 months (Figure 1a).
High levels of URLC10-specific CTLs (44.6% of CD8-
positive cells) were identified after 4 courses of vaccination.
We also observed the relationship between delayed type
hypersensitivity (DTH) as RAI and clinical responses. The
stronger the RAI became, the better the clinical responses
were, indicating that the RAI seems to be a good bio-
marker to predict the clinical response (Table 5).
Survival analysis
To clarify the prognostic factors in our vaccine treatment,
we further analyzed the survival of patients as shown in
Figure 2a, Additional 2: Figure S1 and Table 6. The 1-year
survival rate was 58.3% and the median survival period
was calculated as being 398 days (56.9 weeks). SensitiveTable 5 Reaction at injection site and clinical response
Clinical response RAI: Grade 0 RAI: Grade 1 RAI: Grade 2
Stable disease 0 3 4
Progressive disease 2 6 0
Numbers shown: mean number of patients; RAI: reaction at injection site.
p=0.026 (Fisher’s exact test).EGFR mutations were found in patients 5 and 12. Patient
10 was treated with Erlotinib as the follow-up therapy, al-
though this patient was found to have no EGFR mutation.
The EGFR mutation in patient 5 was found after the vac-
cine therapy was terminated and was subsequently treated
with an EGFR-tyrosine kinase inhibitor (EGFR-TKI).
However, because of the poor PS, this patient did not tol-
erate EGFR-TKI. An EGFR mutation was also detected in
patient 12 after the vaccine therapy, but this patient was
also treated using cytotoxic chemotherapy because they
wished to receive it.
As shown in Table 6, PS, CTL response and pre-
treatment C-reactive protein (CRP) level (≥1.0 mg/ml)
were indicated to be statistically significant prognostic
factors (p=0.0004, 0.0176 and 0.0284, respectively).
Since these three parameters were correlated with each
other, further investigation of patients with good PS is
essential in the evaluation of the contribution of CTL
induction to good prognosis. The number of treatment
regimens undergone before enrollment into the vaccine
therapy also showed some tendency to influence overall
survival (p=0.0629). No other laboratory and immuno-
logical parameter, including the proportion of regulatory
















Median survival time: 398 days

















Multiple strong CTL induction
No/ single strong CTL response 
1-year survival rate: 85.7% 





Figure 2 Survival analysis of patients. (a) Overall survival curve for the fifteen patients analyzed using the Kaplan-Meier method. The median
survival time is 398 days and the 1-year survival rate is 58.3%. (b) Overall survival curve according to the CTL responses (Kaplan-Meier method). Patients
with strong positive CTL responses (+++) to two or more peptides (n=7) had a significantly better prognosis than those revealing a strong CTL
response to no or only one peptide (n=8, including several patients who had weak CTL responses with + or ++ against multiple peptides. ) (p=0.0176
using the log-rank test). The 1-year survival rates for the group showing a CTL response with multiple peptides and those with no or a single peptide
are 85.7% and 33.3%, respectively. As mention above the cutoff levels for CTL were set as (−, +, ++) vs. (+++) in survival analysis.
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vival and the number of peptides for which we observed
CTL responses. As shown in Figure 2b, patients with CTL
induction against multiple peptides had a significantly
higher survival rate than those with CTL induction against
a single peptide or no peptide, suggesting an advantage in
using multiple peptides for cancer treatment.
Discussion
Among the large number of therapeutic cancer vaccine
trials for solid tumors being conducted worldwide, most
involve the administration of a single vaccine [15,16].
For lung cancer, two large phase 3 trials using MAGE-A3
or BLP25 are expected to be very promising (ClinicalTrials.gov NCT00480025 and NCT01015443) [5,6]. However,
single vaccine therapies in these trials may have some dis-
advantages as compared with treatment involving a mix-
ture of multiple peptides derived from multiple proteins;
one important factor is that antigen expression occurs in a
relatively limited proportion of tumors. For example, the
expression of MAGE-A3 has been reported in only 40% of
cases [17], and in only 24% of Japanese patients [18]. The
other important issue is the frequency of CTL induction,
the rate of which largely depends on the nature of individ-
ual antigens. In fact, two lung cancer studies reported pre-
viously shown CTL induction in only 20-53% of the cases
treated with vaccines [6,19]. In this regard as recently
reported, treatment using multiple vaccine therapy has










< 60y 50 213 0.4159
Sex
Male 66.7 476
Female 0 282 0.4797
Performance status
0-1 100 834
2 0 112 0.0004
Treatment line
~2nd 72.9 834
3rd~ 42.9 112 0.0629
Reaction at injection site
Strong 75.0 476
Weak 50.9 398 0.5207
CTL
Strong 85.7 -
Weak 33.3 112 0.0176
Regulatory T (%)
High 57.1 476
Low 33.3 282 0.3856
C-reactive protein
>=1.0 25.0 53
< 1.0 71.6 834 0.0284
Hemoglobin
Normal 57.1 834
Low 56.3 398 0.891
Albumin
Normal 57.1 834
Low 62.5 398 0.8256
White blood cell count
High 55.6 -
Normal 66.7 398 0.7070
Neutrophile (%)
High 75.0 834
Low 38.1 282 0.1902
Lymphocyte (%)
High 50.0 282
Low 66.7 398 0.5006
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tion may be higher for one or more antigens [7,8]. Further
in renal cell cancer, clinical benefits have been shown lately
using a multiple peptide vaccination named IMA901, and
a phase 3 study is currently ongoing [20]. In the present
study, we have conducted a vaccine trial for lung cancer
using multiple peptide vaccines, and observed that the spe-
cific CTL responses against one or more epitope peptides
were very effective. In only two out of the 15 patients, no
CTL induction was observed using any of the four pep-
tides. Although we administered our vaccine treatment to
the patients as a second line or later treatment, they
achieved a median survival time of 398 days and a 1-year
survival rate of 58.3%. Previous major second line trial data
regarding NSCLC using a cytotoxic chemotherapeutic drug
revealed a median survival time of about ~8 months and a
1-year survival rate of ~30% [21]. Hence, we expect that
our vaccine formulation may contribute to an improve-
ment in the prognosis of patients with NSCLC, although
further investigation of survival benefit using a larger num-
ber of patients is required.
Peptide vaccines used in this trial included peptides that
originated from VEGFR1 and VEGFR2 for targeting
angiogenesis in tumors. Bevacizmab, an antibody targeting
VEGF, has already been used to treat the advanced non-
squamous type of NSCLC [22]. Although anti-angiogenic
therapy alone does not have sufficient efficacy to induce
tumor shrinkage [23], it may support the induction of a
strong anti-tumor effect and/or contribute to improved
patient survival when it is combined with other therapies
[24,25]. Therefore, we considered that the combination
of anti-angiogenic peptides with peptides derived from
tumor-specific antigen-proteins may cause a synergistic
clinical effect in patients with NSCLC. In addition, since
HLA molecules are down-regulated in many types of
advanced solid cancer including lung cancer [26,27], pep-
tides targeting blood vessels in which HLA molecules are
stably expressed should have some anti-tumor effect by
reducing the blood supply to tumors.
In our vaccine trial, although we did not observe tumor
shrinkage, we observed a possible survival benefit. “Clin-
ical benefit without tumor shrinkage” is considered to be
one of the characteristics of cancer vaccine treatment
[28]. In fact, the guidance for therapeutic cancer vac-
cines released from the Food and Drug Administration
(FDA) in the United States that was released in 2011
(http://www.fda.gov/downloads/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/
Vaccines/UCM278673.pdf ) mentioned that therapeutic
cancer vaccine treatment can provide a survival benefit
without evident tumor shrinkage. The FDA guidance fur-
ther commented that “clinical progression that is asymp-
tomatic and/or is not likely to result in life-threatening
complications with further progression (e.g., central
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from bony metastases) may not be sufficient reason for
discontinuation of the administration of a cancer vaccine”.
Accumulating evidence has indicated the necessity of
establishing novel criteria for the evaluation of clinical
response in immunotherapy such as immune-related re-
sponse criteria (irRC) [28]. Researchers have started using
overall survival or relapse-free survival in recently conducted
trials as endpoints in immunotherapy clinical trials.
Our data suggested that PS, CTL induction and pre-
treatment serum CRP level might be potential predictive
markers for vaccine treatment. Extensive and systematic
approaches regarding biomarker discovery for vaccine
therapy have been carried out [29]. In addition, several
prognostic factors possibly related to immunotherapy in-
cluding clinico-pathological parameters or immunological
parameters have been reported [30]. Some previous stu-
dies have implicated PS and CTL as good prognostic fac-
tors [31,32] in line with our findings. However, although
our study has suggested that patients with a higher CRP
level (≥1.0 mg/ml) had significantly shorter survival times
than those with a lower CRP level, the usefulness of CRP
as a prognostic marker has been controversial [33,34].
The US FDA guidance also suggests that cancer vaccine
should be administered to patients at an earlier stage, at
which the immune system has not been heavily damaged
by cytotoxic anti-cancer drugs. In this regard, administra-
tion of vaccine therapy should be more appropriate as an
adjuvant treatment after surgery, or as an early phase
treatment after relapse of the disease in combination with
or without chemotherapy.
In summary, we conducted phase I trials with multiple
peptide vaccines for patients with NSCLC. These vaccine
treatments were well tolerated and prolongation of patient
survival owing to vaccine treatment might be expected.
We believe that vaccine treatment using multiple peptides
is likely to be very promising, although this should be vali-
dated by further advanced-phase clinical trials.Additional files
Additional file 1: Table S2. Summary of Elispot assay data, before, post
1 course and post 2 course vaccination.
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